We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Groupe Crit | EU:CEN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.60 | -0.81% | 73.60 | 73.40 | 74.00 | 74.40 | 73.60 | 74.00 | 1,801 | 17:00:00 |
RNS Number:8019Q CeNeS Pharmaceuticals PLC 13 October 2003 CeNeS announces additional data supporting the potential of M6G as an alternative to morphine in the treatment of pain Cambridge, UK, 13th October 2003 - CeNeS Pharmaceuticals plc (LSE: CEN) today announced additional data produced by external academic groups. This data strongly supports the potential of M6G (morphine-6-glucuronide) for the treatment of post-operative pain. The data is being presented at three major European and North American pain conferences. M6G is currently in phase III of its clinical development programme for the treatment of post-operative pain. The results from the first phase III study will be available in mid 2004. Key findings from six academic presentations are shown below: *In healthy volunteer studies, M6G was shown to produce potent and long lasting analgesia with similar potency in both men and women. Compared to morphine, M6G produces significantly fewer side effects such as respiratory depression, nausea and vomiting. *In 3 post-operative patient studies (272 patients in total), M6G was shown to produce equivalent analgesia to morphine. Trends were observed indicating the beneficial effects of M6G compared to morphine, including respiratory depression, nausea and vomiting. *The pharmacokinetics of M6G is discussed, for example that the apparent longer duration of action of M6G compared to morphine is due to M6G reaching higher concentrations in the brain ECF (extra cellular fluid) and CSF (cerebrospinal fluid). Commenting on these presentations, Neil Clark, Chief Operating Officer and Financial Director of CeNeS said, " This new data support our own clinical findings and our belief in the potential of M6G as a new drug for the treatment of acute pain with significant advantages over morphine and other opiates." The conferences at which the M6G data has been presented are: *2nd-4th September; Congress of the European Federation of the International Association of the Study of Pain Chapters - Prague *10th October; 4th International Symposium for Nociceptive/Neuropathic Pain - King's College London *13th-14th October, American Society of Anesthesiologists Annual Meeting, San Francisco Full details of the data presented will be available in academic papers to be issued in due course. This news release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process. For more information please contact: CeNeS Pharmaceuticals plc Neil Clark Tel: +44 (0)1223 266466 Fax: +44 (0)1223 266467 Notes to Editors: CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control. The company has development assets targeting pain and has a portfolio of carried interests in assets that it has divested. The company is based in Cambridge, England. For further information visit www.cenes.co.uk. M6G M6G, a natural metabolite of morphine, is in development by CeNeS for the treatment of moderate to severe pain. Morphine is a highly effective analgesic that has been used for many years despite the unpleasant side effects of nausea and vomiting and the potential dangers of respiratory depression. M6G has undergone several Phase II clinical trials with more than 450 patients receiving the compound. The most recent Phase II trials were designed to establish the analgesic effects of different doses of M6G administered at different times compared to a standard morphine treatment regime. Phase III efficacy studies are currently being undertaken: a pivotal, dose-ranging placebo controlled study is scheduled to commence as a multi-centre study in Europe in 2003 in patients undergoing knee replacement surgery with spinal anaesthesia. It is planned that this will be followed by a second Phase III trial in Europe comparing M6G and morphine treatment in patients with postoperative pain following gastrointestinal and gynaecological surgery. Side-effect profiles of M6G will be investigated in both studies. If these trials are successful then M6G will be on target to be launched in Europe in 2006. Opiate Analgesia Analgesia is the process of pain-relief and any pain-relieving drug is called an analgesic. The most potent known class of analgesics are the opiates, derived from the opium poppy, which confer a high degree of pain-relief for severe pain. Opiates, like morphine and codeine, act centrally in the brain in an area called the periaqueductal grey area where they mimic the actions of neuromodulators called endogenous opiates and 'switch off' the sensation of pain centrally. The markets for M6G M6G has potential as an analgesic for two types of pain, post-operative pain and chronic pain, both of which are currently treated with morphine. The global market for narcotic analgesics is estimated at $4 billion. This information is provided by RNS The company news service from the London Stock Exchange END RESDBLFFXBBXFBL
1 Year Groupe Crit Chart |
1 Month Groupe Crit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions